Aluminum Zirconium Pentachlorohydrex Gly
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Zirconium Pentachlorohydrex Gly
- Aluminum Zirconium Pentachlorohydrex Gly: Insufficient Data for Repurposing Evaluation
Aluminum Zirconium Pentachlorohydrex Gly: Insufficient Data for Repurposing Evaluation
One-Sentence Summary
Aluminum Zirconium Pentachlorohydrex Gly is an aluminum-based compound most commonly used as an active ingredient in antiperspirant formulations, functioning by forming temporary plugs in sweat ducts. The TxGNN model returned no predicted indications for this compound, and no clinical trials or publications could be linked to a repurposing candidate. This evaluation cannot proceed to a standard evidence review without additional input data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication on record |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and no prediction was generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No prediction was generated by TxGNN for this compound, so a mechanistic rationale cannot be constructed.
Currently, detailed mechanism of action data is not available. Based on known information, Aluminum Zirconium Pentachlorohydrex Gly is an aluminum-zirconium salt complex used as an antiperspirant active ingredient. It is understood to act locally on eccrine sweat glands, forming aluminum hydroxide gel plugs that reduce perspiration. It is not typically classified as a systemic pharmaceutical agent, which likely explains why the TxGNN knowledge graph — built on DrugBank and pharmacological interaction networks — did not return any repurposing candidates.
Without a DrugBank ID and without approved pharmaceutical indications in any regulatory dataset, the compound falls outside the scope of standard drug repurposing workflows. Its primary domain is cosmetic/topical OTC use rather than prescription therapy, and the evidence infrastructure required to support a repurposing evaluation (MOA annotation, disease association in KG, clinical trial linkage) is entirely absent.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No authorizations on record. This compound has zero approved drug licenses in the regulatory database queried.
Note: Aluminum Zirconium Pentachlorohydrex Gly is widely used as an OTC antiperspirant active (typically at 10–20% in consumer products) but is regulated as a cosmetic/OTC monograph ingredient rather than as a prescription drug product. This classification places it outside the scope of standard NDA/license tracking systems.
Safety Considerations
Please refer to the package insert for safety information. No pharmacovigilance data, contraindications, or drug–drug interaction records were found in the queried databases.
Conclusion and Next Steps
Decision: Hold
Rationale: This compound currently has zero predicted repurposing indications, no regulatory drug approvals, no MOA data in the knowledge graph, and no clinical or literature evidence to evaluate. A standard repurposing workflow cannot be executed without foundational data.
To proceed, the following is needed:
- Confirm compound classification: Determine whether this compound is being evaluated as a pharmaceutical drug candidate or as an OTC/cosmetic active. If the latter, a different evidence framework (e.g., cosmetic safety dossier) applies.
- Obtain DrugBank ID or equivalent: Without a DrugBank ID, the TxGNN model cannot anchor the compound to its knowledge graph. Manual curation or mapping to a pharmacologically equivalent compound (e.g., aluminum chlorohydrate, aluminum chloride) may be required.
- Define the target indication: If a specific new indication is hypothesized (e.g., primary hyperhidrosis as a prescription indication, or an oncology-adjacent wound/skin application), that hypothesis must be specified before evidence collection can begin.
- Download and parse full package insert: If any prescription formulation exists, the TFDA or FDA package insert (PDF) should be parsed to extract warnings, contraindications, and approved indications.
- Re-run TxGNN with mapped compound: Once a DrugBank ID or KG node is established, re-run the prediction pipeline to generate candidate indications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.